NEW YORK, Jan. 30, 2018 -- Prospect Capital Corporation (NASDAQ:PSEC) (or “Company”) announced today that it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing its second fiscal quarter results for the three and six months ended December 31, 2017 on Wednesday, February 7, 2018 after the close of the markets. The Company also expects to issue its earnings press release on Wednesday, February 7, 2018 after the close of the markets.
The Company will host a conference call on Thursday, February 8, 2018 at 11:00 a.m. Eastern Time. The conference call dial-in number will be 888-338-7333. A recording of the conference call will be available for approximately 30 days. To hear a replay, call 877-344-7529 and use passcode 10116503.
The conference call will also be available via a live listen-only webcast on the Company’s website, www.prospectstreet.com. Please allow extra time prior to the call to visit the site and download any necessary software that may be needed to listen to the Internet broadcast. A replay of the audio webcast will be available on the Company's website for approximately 30 days following the conference call.
ABOUT PROSPECT CAPITAL CORPORATION
Prospect Capital Corporation (www.prospectstreet.com) is a business development company that focuses on lending to and investing in private businesses. Our investment objective is to generate both current income and long-term capital appreciation through debt and equity investments.
We have elected to be treated as a business development company under the Investment Company Act of 1940 (“1940 Act”). We are required to comply with a series of regulatory requirements under the 1940 Act as well as applicable NASDAQ, federal and state rules and regulations. We have elected to be treated as a regulated investment company under the Internal Revenue Code of 1986. Failure to comply with any of the laws and regulations that apply to us could have an adverse effect on us and our shareholders.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, whose safe harbor for forward-looking statements does not apply to business development companies. Any such statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that we may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements. Such statements speak only as of the time when made, and we undertake no obligation to update any such statement now or in the future.
For additional information, contact:
Grier Eliasek, President and Chief Operating Officer
[email protected]
Telephone (212) 448-0702


Anta Sports Expands Global Footprint With Strategic Puma Stake
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Samsung Electronics Shares Jump on HBM4 Mass Production Report
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 



